CAR-T Meeting 2025 | Updates on ongoing projects of the GoCART coalition
Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, provides an update on the GoCART coalition, highlighting its goal of bringing together stakeholders to address pressing issues in CAR-T and other cellular therapies. The coalition’s activities are structured in five working groups, including two focused on analyzing determinants of outcome using data from over 12,000 patients treated with CAR-T. Prof. Chabannon notes that despite efforts to improve data collection, there is currently no consensus on how to capture certain information, emphasizing the need for ongoing collaboration to enhance the quality and quantity of data. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
The GoCART Coalition is a project and a community that was started five years ago during the second European CAR T-cell meeting in Sitges in Spain. And the goal was to bring all stakeholders that are interested in the development and the treatments with CAR T-cells and now with other forms of immune effector cells-based therapies to sit together and to try to tackle some of the most pressing issues in the field...
The GoCART Coalition is a project and a community that was started five years ago during the second European CAR T-cell meeting in Sitges in Spain. And the goal was to bring all stakeholders that are interested in the development and the treatments with CAR T-cells and now with other forms of immune effector cells-based therapies to sit together and to try to tackle some of the most pressing issues in the field.
Yes, that was the goal of the presentation this morning, so the GoCART activities are structured in five working groups. Two of those groups deal with collecting data on CAR-T-treated patients and then using this data to analyze determinants of the outcome. In terms of collecting data, we are taking advantage of the European EBMT registry that has now registered more than 12,000 patients treated with CAR T-cells and keep collecting long, middle, and short-term follow-up for those patients.
And the Scientific Excellence Working Group has launched four annual calls and selected now 11 projects that are given accelerated support to carry out studies that look at different aspects of CAR T-cell therapies.
In terms of data collection, one recent initiative was what we call the Delphi survey that was discussed at length yesterday morning in the context of a meeting, a joint EBMT-GoCART coalition T2EVOLVE meeting. And the goal was to define what kind of information needs to be added to the existing registry. How can we improve the format in which we capture information, and maybe the most striking conclusion of this meeting to me was that for many informations, there is no definitive consensus on how we should capture this information. So we keep this process going as it helps us improve the quality and quantity of data that we collect in the registry.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
